Subject:
|
Radboudumc 2: Cancer development and immune defence RIMLS: Radboud Institute for Molecular Life Sciences |
Organization:
|
Medical Oncology Tumorimmunology |
Abstract:
|
Currently three bona fide dendritic cell (DC) types are distinguished in human blood. Herein we focus on type 2 DCs (DC2s) and compare the three defining markers CD1c, CD172, and CD301. When using CD1c to define DC2s, a CD14(+) and a CD14(-) subset can be detected. The CD14(+) subset shares features with monocytes, and this includes substantially higher expression levels for CD64, CD115, CD163, and S100A8/9. We review the current knowledge of these CD1c(+)CD14(+) cells as compared to the CD1c(+)CD14(-) cells with respect to phenotype, function, transcriptomics, and ontogeny. Here, we discuss informative mutations, which suggest that two populations have different developmental requirements. In addition, we cover subsets of CD11c(+)CD8(-) DC2s in the mouse, where CLEC12A(+)ESAM(low) cells, as compared to the CLEC12A(-)ESAM(high) subset, also express higher levels of monocyte-associated markers CD14, CD3, and CD115. Finally, we summarize, for both man and mouse, the data on lower antigen presentation and higher cytokine production in the monocyte-marker expressing DC2 subset, which demonstrate that the DC2 subsets are also functionally distinct.
|